Health Canada Approves Catena® for Treatment of Friedreich’s Ataxia

News Release Liestal, Switzerland, July 24, 2008 – Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich’s Ataxia. Health Canada’s decision is the first marketing authorization worldwide for any Friedreich’s Ataxia therapy....

Continue reading

Cardiac problems in Friedreich’s Ataxia

Around 90% of patients afflicted with Friedreich’s Ataxia (FA) eventually show cardiac symptoms. In general, ataxia precedes the beginning of the cardiac symptoms. With most patients, it involves a cardiac disease called left ventricular hypertrophy. Left ventricular hypertrophy is an increase in the thickness of the wall and of the...

Continue reading

Clinical study on HDACIs… (2009)

By Guy D’Anjou, M.D. FRCPC Neurologist, Sainte-Justine Hospital Friedreich’s ataxia (FA) is one of the most frequent neurodegenerative diseases. Its clinical manifestations appear at a critical stage in the development of an individual and affect his autonomy and quality of life. A number of years ago it was discovered that...

Continue reading